Frank Aldridge, CFA
Long/short equity, small-cap

Trouble For Synergy Pharmaceuticals Shorts With Pending SP-333 Trial Results

I wrote an article about Synergy Pharmaceuticals (NASDAQ:SGYP) ("Synergy" or "the company") in November of last year right before the stock made a significant move leading up to Phase 2 IBS-C results. You can refer to my previous article for more info on the company and the product pipeline they are developing.

A few quick highlights on what has occurred since my November 2013 article are as follows:

    November 13, 2013: Initiated first P3 trial for Plecanatide for treatment of CIC April 28, 2014: Initiated second P3 trial for Plecanatide for treatment of CIC April 30, 2014: Reported positive results for Phase 2 trial of Plecanatide for treatment of IBS-C July 17, 2014: Reported completion of enrollment for ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details